Novel centrosome protein, TCC52, is a cancer-testis antigen.
A novel centrosome protein, TCC52, was identified as a cancer-testis (CT) antigen. The TCC52 gene was tissue-restricted in normal tissues but highly expressed in lung cancer tissues and some cancer cell lines. Immunoglobulin G antibody specific to TCC52 was detected in serum samples from patients with prostate cancer (59.4%, 69/116), cholangiocarcinoma (17.6%, 6/34), laryngeal cancer (8%, 8/100) and lung cancer (5.6%, 4/71) in patients, rather than from healthy donors. Based on its restricted expression pattern and immunogenicity in some types of tumor, TCC52, as a novel CT antigen, would be a promising candidate for cancer immunotherapy.
Li
Sichen
S
Key laboratory of Cell Proliferation and Regulation of Ministry of Education, Beijing Normal University, Beijing, China.
Hu
Xiaohua
X
Cui
Shuang
S
He
Dacheng
D
D000951:Antigens, Neoplasm / Q000235:genetics / Q000276:immunology* / Q000378:metabolism*; D045744:Cell Line, Tumor; D018385:Centrosome / Q000276:immunology / Q000378:metabolism*; D020869:Gene Expression Profiling; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D009369:Neoplasms / Q000276:immunology* / Q000378:metabolism; D013737:Testis / Q000276:immunology* / Q000378:metabolism
D000951:Antigens, Neoplasm; C534520:DCAF12 protein, human